Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models

Thierry Menguy(Cherry Biotech (France)), Philippe Le Bouteiller(Inserm)
Investigative Ophthalmology & Visual Science
June 1, 2018
Cited by 10


Related Papers